Real-world flash glucose monitoring patterns and associations between self-monitoring frequency and glycaemic measures: A European analysis of over 60 million glucose tests

被引:170
作者
Dunn, Timothy C. [1 ]
Xu, Yongjin [1 ]
Hayter, Gary [1 ]
Ajjan, Ramzi A. [2 ]
机构
[1] Abbott Diabet Care, 1360 South Loop Rd, Alameda, CA 94502 USA
[2] Univ Leeds, LIGHT Labs, Leeds Inst Cardiovasc & Metab Med, Leeds LS2 9JT, W Yorkshire, England
基金
美国国家卫生研究院;
关键词
Flash glucose monitoring; Blood glucose monitoring frequency; Real-world data; Glycaemic measures; AMERICAN-DIABETES-ASSOCIATION; BLOOD-GLUCOSE; POSITION STATEMENT; CARDIOVASCULAR-DISEASE; SENSING TECHNOLOGY; CLINICAL-TRIALS; HYPOGLYCEMIA; MULTICENTER; MANAGEMENT; TYPE-1;
D O I
10.1016/j.diabres.2017.12.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aims: Randomised controlled trials demonstrate that using flash glucose monitoring improves glycaemic control but it is unclear whether this applies outside trial conditions. We investigated glucose testing patterns in users worldwide under real life settings to establish testing frequency and association with glycaemic parameters. Methods: Glucose results were de-identified and uploaded onto a dedicated database once readers were connected to an internet-ready computer. Data between September 2014 and May 2016, comprising 50,831 readers and 279,446 sensors worldwide, were analysed. Scan rate per reader was determined and each reader was sorted into twenty equally-sized rank-ordered groups, categorised by scan frequency. Glucose parameters were calculated for each group, including estimated HbA(1c), time above, below and within range identified as 3.9-10.0 mmol/L. Results: Users performed a mean of 16.3 scans/day [median (IQR): 14 (10-20)] with 86.4 million hours of readings and 63.8 million scans. Estimated HbA(1c) gradually reduced from 8.0% to 6.7% (64 to 50 mmol/mol) as scan rate increased from lowest to highest scan groups (4.4 and 48.1 scans/day, respectively; p < .001). Simultaneously, time below 3.9, 3.1 and 2.5 mmol/L decreased by 15%, 40% and 49%, respectively (all p < .001). Time above 10.0 mmol/L decreased from 10.4 to 5.7 h/day (44%, p < .001) while time in range increased from 12.0 to 16.8 h/day (40%, p < .001). These patterns were consistent across different countries. Conclusions: In real-world conditions, flash glucose monitoring allows frequent glucose checks with higher rates of scanning linked to improved glycaemic markers, including increased time in range and reduced time in hyper and hypoglycaemia. (C) 2017 Abbott Diabetes Care. Published by Elsevier Ireland Ltd.
引用
收藏
页码:37 / 46
页数:10
相关论文
共 27 条
[1]   Glucose Concentrations of Less Than 3.0 mmol/L (54 mg/dL) Should Be Reported in Clinical Trials: A Joint Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes [J].
Amiel, Stephanie A. ;
Aschner, Pablo ;
Childs, Belinda ;
Cryer, Philip E. ;
de Galan, Bastiaan E. ;
Heller, Simon R. ;
Gonder-Frederick, Linda ;
Frier, Brian M. ;
Jones, Timothy ;
Khunti, Kamlesh ;
Leiter, Lawrence A. ;
McCrimmon, Rory J. ;
Luo, Yingying ;
Seaquist, Elizabeth R. ;
Vigersky, Robert ;
Zoungas, Sophia .
DIABETES CARE, 2017, 40 (01) :155-157
[2]   Glucose concentrations of less than 3.0 mmol/l (54 mg/dl) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the Europian Association for the Study of Diabetes [J].
Amiel, Stephanie A. ;
Aschner, Pablo ;
Childs, Belinda ;
Cryer, Philip E. ;
de Galan, Bastiaan E. ;
Heller, Simon R. ;
Frier, Brian M. ;
Gonder-Frederick, Linda ;
Jones, Timothy ;
Khunti, Kamlesh ;
Leiter, Lawrence A. ;
McCrimmon, Rory J. ;
Luo, Yingying ;
Seaquist, Elizabeth R. ;
Vigersky, Robert ;
Zoungas, Sophia .
DIABETOLOGIA, 2017, 60 (01) :3-6
[3]  
[Anonymous], GLYC TARG DIAB CA S1
[4]  
[Anonymous], 2016, ANN DIAB REP 2016
[5]  
[Anonymous], NEW ENGL J MED
[6]  
Benjamin E.M., 2002, Clinical Diabetes, V20, P45, DOI DOI 10.2337/DIACLIN.20.1.45
[7]   Recommendations for Standardizing Glucose Reporting and Analysis to Optimize Clinical Decision Making in Diabetes: The Ambulatory Glucose Profile (AGP) [J].
Bergenstal, Richard M. ;
Ahmann, Andrew J. ;
Bailey, Timothy ;
Beck, Roy W. ;
Bissen, Joan ;
Buckingham, Bruce ;
Deeb, Larry ;
Dolin, Robert H. ;
Garg, Satish K. ;
Goland, Robin ;
Hirsch, Irl B. ;
Klonoff, David C. ;
Kruger, Davida F. ;
Matfin, Glenn ;
Mazze, Roger S. ;
Olson, Beth A. ;
Parkin, Christopher ;
Peters, Anne ;
Powers, Margaret A. ;
Rodriguez, Henry ;
Southerland, Phil ;
Strock, Ellie S. ;
Tamborlane, William ;
Wesley, David M. .
DIABETES TECHNOLOGY & THERAPEUTICS, 2013, 15 (03) :198-211
[8]   Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial [J].
Bolinder, Jan ;
Antuna, Ramiro ;
Geelhoed-Duijvestijn, Petronella ;
Kroeger, Jens ;
Weitgasser, Raimund .
LANCET, 2016, 388 (10057) :2254-2263
[9]  
Elwen FR, 2015, BMJ OPEN DIAB RES CA, V3, DOI [10.1136/bmjdrc-2015000094, 10.1136/bmjdrc-2015-000094]
[10]   Hypoglycemia and Cardiovascular Risks [J].
Frier, Brian M. ;
Schernthaner, Guntram ;
Heller, Simon R. .
DIABETES CARE, 2011, 34 :S132-S137